Form 4 for GNLX GENELUX Corp
Accepted 2025-12-11 00:00:00 ET · period of report 2025-08-21 · accession 0001493152-25-027338 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-12-11 | 2025-08-21+ | GNLX | Yu Yong | SVP, Clinical Development | S - Sale | $3.83 | -4,192 | 145.8K | -3% | -$16.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-21 | S | D | 3,219 | $3.36 | 146,817 | D | — | — | (F2) The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025. |
| 2 | Common | Common Stock | 2025-11-17 | S | D | 973 | $5.37 | 145,844 | D | — | — | (F2) The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025. |